MedTrace Logo

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

NCT06550882 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2026-05-19

No results posted yet for this study

Summary

Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.

The main aim of the study is to learn how safe OBIZUR is in adults with AHA.

Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.

The treatment of the participants will be determined by the treating physicians.

During the study, data already existing in the participants' medical record and new data will be collected.

Conditions

  • Acquired Hemophilia A

Interventions

DRUG

OBIZUR

OBIZUR injection.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06550882 on ClinicalTrials.gov